PL2356090T3 - Formy krystaliczne Fingolimodu HCI - Google Patents

Formy krystaliczne Fingolimodu HCI

Info

Publication number
PL2356090T3
PL2356090T3 PL09748350T PL09748350T PL2356090T3 PL 2356090 T3 PL2356090 T3 PL 2356090T3 PL 09748350 T PL09748350 T PL 09748350T PL 09748350 T PL09748350 T PL 09748350T PL 2356090 T3 PL2356090 T3 PL 2356090T3
Authority
PL
Poland
Prior art keywords
crystalline forms
fingolimod hcl
fingolimod
hcl
crystalline
Prior art date
Application number
PL09748350T
Other languages
English (en)
Polish (pl)
Inventor
Michael Mutz
Guido Jordine
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2356090T3 publication Critical patent/PL2356090T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL09748350T 2008-11-11 2009-11-10 Formy krystaliczne Fingolimodu HCI PL2356090T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08168865 2008-11-11
EP09748350.7A EP2356090B1 (en) 2008-11-11 2009-11-10 Crystalline forms of fingolimod hcl
PCT/EP2009/064891 WO2010055028A2 (en) 2008-11-11 2009-11-10 Organic compounds

Publications (1)

Publication Number Publication Date
PL2356090T3 true PL2356090T3 (pl) 2017-12-29

Family

ID=40521487

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09748350T PL2356090T3 (pl) 2008-11-11 2009-11-10 Formy krystaliczne Fingolimodu HCI

Country Status (14)

Country Link
US (2) US8530522B2 (enExample)
EP (1) EP2356090B1 (enExample)
JP (4) JP2012508216A (enExample)
KR (2) KR101393994B1 (enExample)
CN (3) CN104788325A (enExample)
AU (1) AU2009315736B2 (enExample)
BR (1) BRPI0921826A2 (enExample)
CA (1) CA2743232C (enExample)
ES (1) ES2643161T3 (enExample)
MX (1) MX2011004962A (enExample)
PL (1) PL2356090T3 (enExample)
PT (1) PT2356090T (enExample)
RU (2) RU2015111229A (enExample)
WO (1) WO2010055028A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2746939T3 (es) * 2010-10-01 2020-03-09 Synthon Bv Procedimiento para la preparación de cristales de clorhidrato de fingolimod
PL2632889T3 (pl) 2010-10-28 2019-04-30 Mapi Pharma Ltd Związki pośrednie i sposób wytwarzania fingolimodu
WO2012071524A1 (en) 2010-11-24 2012-05-31 Ratiopharm Gmbh Arylsulfonate salts of fingolimod and processes for preparation thereof
EP2646409A4 (en) * 2010-11-25 2015-12-16 Shilpa Medicare Ltd FINGOLIMOD POLYMORPHES AND METHOD THEREFOR
ES2746016T3 (es) 2010-12-28 2020-03-04 Synthon Bv Procedimiento para la preparación de cristales de clorhidrato de fingolimod
WO2012097330A2 (en) * 2011-01-14 2012-07-19 University Of Washington Compositions and methods for treating degenerative muscle conditions
EP2702034A4 (en) 2011-04-29 2015-03-25 Reddys Lab Ltd Dr PREPARATION OF FINGOLIMOD AND ITS SALTS
US9751834B2 (en) 2011-05-26 2017-09-05 Gri Bio, Inc. Oxygenated amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use
DK2739606T3 (en) 2011-05-26 2016-07-25 Jado Tech Gmbh Hydroxy-substituted amino and ammonium derivatives and their medical use
EP3610868B1 (en) 2011-05-26 2025-02-19 GRI Bio, Inc. Amino- or ammonium-containing sulfonic acid derivatives and their medical use
WO2013019872A1 (en) 2011-08-01 2013-02-07 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions comprising fingolimod
WO2013091704A1 (en) * 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
CN102887829B (zh) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
EP2945927A4 (en) * 2013-01-17 2017-01-18 Shilpa Medicare Limited Process for preparation of fingolimod and its salts
EP2964210B1 (en) * 2013-03-05 2023-10-04 Biocon Limited A process for the preparation of 2-amino-1,3-propane diol compounds and salts thereof
EP3027174B1 (en) 2013-07-29 2019-07-24 Aizant Drug Research Solutions Private Limited Pharmaceutical compositions of fingolimod
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
RU2627691C1 (ru) * 2016-07-06 2017-08-10 Олег Ростиславович Михайлов Кристаллическая η-модификация 2-амино-2-(2-(4-октилфенил)этил)пропан-1,3-диол гидрохлорида, способ её получения и фармацевтическая композиция на её основе
CN106667981B (zh) * 2017-01-16 2019-05-14 南京医科大学第二附属医院 盐酸芬戈莫德在制备治疗药物性肝损伤药物中的应用
CN106860440A (zh) * 2017-01-16 2017-06-20 南京医科大学第二附属医院 盐酸芬戈莫德在制备治疗系统性红斑狼疮脑病药物中的应用
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
WO2020245775A1 (en) * 2019-06-05 2020-12-10 Biocon Limited Crystalline forms of 2-amino-2-(2-(4-octylphenyl) ethyl) propane-1,3-diol
MX2022005014A (es) 2019-10-31 2022-05-16 Idorsia Pharmaceuticals Ltd Combinacion de un antagonista de cxcr7 con un modulador del receptor s1p1.
JP2024521882A (ja) 2021-05-31 2024-06-04 上海雲晟研新生物科技有限公司 フィンゴリモド薬用塩、製造方法、それを含む医薬組成物及び使用
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2579602B2 (ja) 1992-10-21 1997-02-05 吉富製薬株式会社 ２−アミノ−１，３−プロパンジオール化合物および免疫抑制剤
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JP4079505B2 (ja) * 1998-04-28 2008-04-23 田辺三菱製薬株式会社 ２−アミノ−２−［２−（４−オクチルフェニル）エチル］プロパン−１，３−ジオールの新規な製造法
ES2644413T3 (es) * 1998-11-11 2017-11-28 Novartis Ag Producción de 2-amino-2-[2-(4-alquil-fenil)etil]propano-1,3-dioles
PT1031347E (pt) * 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis
US7015218B1 (en) * 1999-02-10 2006-03-21 Mitsubishi Pharma Corporation Amide compounds and medicinal use thereof
CN1144779C (zh) * 1999-03-11 2004-04-07 杭州中美华东制药有限公司 制备2-[2-(4-烷基苯基)-乙基]-2-氨基-丙二醇的方法以及其中制得的中间产物
RU2003136730A (ru) * 2001-06-08 2005-05-20 Новартис АГ (CH) Лечение или профилактика отторжения инсулин-продуцирующего клеточного трансплантата
US20030144712A1 (en) * 2001-12-20 2003-07-31 Jackson Streeter, M.D. Methods for overcoming organ transplant rejection
PT1505959E (pt) * 2002-05-16 2009-02-05 Novartis Ag Utilização de agentes de ligação do receptor edg em cancro
GB0217152D0 (en) * 2002-07-24 2002-09-04 Novartis Ag Organic compounds
NZ592339A (en) * 2003-04-08 2012-09-28 Novartis Ag Solid pharmaceutical compositions of S1P receptor agonist with sugar alcohol
CN1212308C (zh) * 2003-07-24 2005-07-27 漆又毛 2－氨基－2－（2－（4－辛基苯基）乙基）－1，3－丙二醇盐酸盐的制备方法
CN1241903C (zh) * 2003-10-14 2006-02-15 马启明 制备2－对辛基苯乙基－2－氨基丙二醇的方法
TWI418350B (zh) * 2005-06-24 2013-12-11 Sankyo Co 含有ｐｐａｒ調節劑之醫藥組成物的用途
RU2008116578A (ru) * 2005-09-30 2009-11-10 Новартис АГ (CH) Применение ингибиторов dpp-iv для лечения аутоиммунных заболеваний и отторжения трансплантата
CN1310869C (zh) * 2005-11-22 2007-04-18 江苏吴中苏药医药开发有限责任公司 2－氨基－2－[2－(4－烷基苯基)乙基]－1,3－丙二醇的制备方法
CN100548968C (zh) * 2006-03-01 2009-10-14 徐州师范大学 一种制备2-对辛基苯乙基-2-氨基丙二醇盐酸盐的方法
ES2414205T3 (es) * 2006-06-02 2013-07-18 The Ohio State University Research Foundation Agentes terapéuticos para el tratamiento de linfoma de células del manto
KR101686369B1 (ko) * 2006-09-26 2016-12-13 노파르티스 아게 Ｓ１ｐ 조정제를 포함하는 제약 조성물
KR20170081755A (ko) * 2008-06-20 2017-07-12 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
ES2746939T3 (es) 2010-10-01 2020-03-09 Synthon Bv Procedimiento para la preparación de cristales de clorhidrato de fingolimod

Also Published As

Publication number Publication date
JP2014139179A (ja) 2014-07-31
KR20110069156A (ko) 2011-06-22
EP2356090A2 (en) 2011-08-17
JP2012508216A (ja) 2012-04-05
AU2009315736A1 (en) 2010-05-20
RU2549899C2 (ru) 2015-05-10
KR20130109254A (ko) 2013-10-07
KR101393994B1 (ko) 2014-05-14
RU2011123371A (ru) 2012-12-20
US20140051766A1 (en) 2014-02-20
PT2356090T (pt) 2017-10-16
WO2010055028A2 (en) 2010-05-20
US20110229501A1 (en) 2011-09-22
CA2743232A1 (en) 2010-05-20
EP2356090B1 (en) 2017-07-05
RU2015111229A3 (enExample) 2018-11-08
ES2643161T3 (es) 2017-11-21
US8530522B2 (en) 2013-09-10
JP2016028056A (ja) 2016-02-25
WO2010055028A3 (en) 2010-07-08
AU2009315736B2 (en) 2013-08-29
RU2015111229A (ru) 2015-11-20
CN102209705A (zh) 2011-10-05
CN104788325A (zh) 2015-07-22
BRPI0921826A2 (pt) 2016-01-12
JP2018035160A (ja) 2018-03-08
CN107233336A (zh) 2017-10-10
CA2743232C (en) 2015-12-29
MX2011004962A (es) 2011-05-30

Similar Documents

Publication Publication Date Title
PT2356090T (pt) Formas cristalinas de fingolimod, hcl
IL212073A0 (en) Salts of fingolimod
GB0819182D0 (en) Crystalline forms
PL2262793T3 (pl) Formy krystaliczne nilotynibu HCL
ZA201105462B (en) Crystalline insulin-conjugates
IL210322A (en) A crystalline form of sitagliptin malate
GB201001075D0 (en) Crystalline forms
IL218723A0 (en) Substituted amide compound
IL216648A0 (en) Crystalline forms of febuxostat
HRP20181567T1 (hr) Kristalni metiltioninium klorid hidrati - drugi dio
EP2365821A4 (en) CRYSTALLINE FORM OF LINACLOTIDE
GB0902406D0 (en) Crystalline polymorphic form
ZA201202405B (en) Crystallization of 4'-epidaunorubicin x hci
SI2303866T1 (sl) Kristalne oblike natrijevega rabeprazolata
ZA201202097B (en) Crystalline forms of substituted pyrazolopyrimidines
IL200126A (en) A new process for obtaining crystalline form v of agomalatine
ZA201104319B (en) Crystalline forms of a 3-carboxypropyl-aminotetralin compound
IL205451A0 (en) Crystalline forms of tigecycline hydrochloride
EP2160376A4 (en) NEW CRYSTALLINE FORMS OF ATOVAQUON
IL195092A0 (en) Crystalline form of (s)-1-phenylethylammonium (r)-diphenyl-methanesulphinyl-acetate
IL205857A0 (en) Processes for preparation of crystalline tigecyclline form ii
AU2013100530B4 (en) Crystalline forms of fingolimod HCL
HU0800755D0 (en) Novel crystalline forms
IL213288A0 (en) Crystalline forms
GB0817164D0 (en) Crystalline forms